PTOSECTE (64.02)
Approach for aim Prough 077-0200. GM 601-0231
U.S. Palent and Testiment Office; U.S. CEPARTEINS OF COMMENCE
Under the Paperson's Reduction Act of 1950, no persons are required to respond to a control or inflammation unless of control or written.

INFORMATION DISCLOSURE
STATEMENT BY APPLICANT
(Not for submission under 37 CFR 1.99)

Application Number		10825866	
Filing Date		2004-04-16	
Art Unit		IN et al.	
		3767	
		beth MacNeill	
Attorney Docket Numb	ber	CV/04-001	

	_			U.S.I	PATENTS				
Examiner Initial*	Cite No	Patent Number	Kind Code ¹	Issue Date	Name of Patentee or Applicant of cited Document	Pages, Columns, Lines where Relevant Passages or Relevant Figures Appear			
	1	4094318		1978-06-13	Burke et al.				
	2	4464172		1984-08-07	Lichtensfein				
	3	4838856		1989-06-13	Mulreany et al.				
	4	7094216		2006-08-22	Trombley, III et al.				
	5	6866654		2005-03-15	Callan et al.				
If you wis	u wish to add additional U.S. Patent citation information please click the Add button.								
			U.S.F	ATENT APPL	CATION PUBLICATIONS				
Examiner Initial*	Cite No	Publication Number		Publication Date	Name of Patentee or Applicant of cited Document	Pages, Columns, Lines where Relevant Passages or Relevant Figures Appear			
	1	20040242996		2004-12-02	Trombley III et al.				

INFORMATION DISCLOSURE STATEMENT BY APPLICANT (Not for submission under 37 CFR 1.99)

Art Unit		10825866		
		2004-04-16 HN et al.		
		abeth MacNeill		
		Attorney Docket Number		CV/04-001

	2	20040254533	2004-12-16		Schriver et al.					
	3	20040122369		2004-06	-24	Schriver et al.				
If you wish	to ac	dd additional U.S. Publ	ished Ap	plication	citation	n information p	lease click the Ad	d butto	n.	
<u> </u>						ENT DOCUM				
Examiner Initial*	Cite No	Foreign Document Number ³	Countr Code ²		Kind Code ⁴	Publication Date	Name of Patente Applicant of cited Document		Pages, Columns, Lines where Relevant Passages or Relevant Figures Appear	Ţs
	1									
If you wis	h to a	dd additional Foreign F	atent D	ocument	citation	information p	lease click the Ad	butto	n	
	_					ERATURE DO				_
Examiner Initials*	Cite No	Include name of the (book, magazine, jou publisher, city and/or	mal, ser	fal, symp	posium,	catalog, etc),	the article (when date, pages(s), vo	approp	riate), title of the Item ssue number(s),	Τs
	1									
If you wis	h to s	idd additional non-pate	nt literat	ure docu	ment c	itation informa	tion please click th	e Add	button	
ii you wie		as decision from post				ER SIGNATUR				
Examine	Sign	ature					Date Consid	lered		
	- CO. I		dered, v	red. Inc	r not ci	tation is in con	formance with MP with next commun	EP 60	Draw line through a to applicant.	

See Kind Codes of USPTO Palest Documents at year-INSTITUCION or an Exp Dot 0.4. To lets office has been been document by the test inter code (WPO) Clanded off 31, 4. For Japanese palest Occuments, the Palestand of the year of the larged the Engeror must provide the select interior for payant document Clanded off 31, 4. For Japanese palest Occuments, the Palestand of the document under VMPO Standard ST.16 of possible. Applicant is to place a chock man't here if Despite largeage enterior in statubout.

INFORMATION DISCLOSURE STATEMENT BY APPLICANT (Not for submission under 37 GFR 1.99)

Application Number		10825868		
Filing Date		2004-04-16		
First Named Inventor SPO		HN et al.		
Art Unit		3767		
Examiner Name Elizal		beth MacNeill		
Manager Develop Manager		CMM 004		

CERTIFICATION STATEMENT

Please see 37	CFR 1 97 and	1 98 to make the	appropriate selection(s):

	That each item of information contained in the information disclosure statement was first cited in any communication
П	from a foreign patent office in a counterpart foreign application not more than three months prior to the filing of the
_	Information disclosure statement. See 37 CFR 1.97(e)(1).

OR

That no item of information contained in the information disclosure statement was offset in a communication from a foreign pattern office in a counterpart feeting application, and, to the investedge of the person aligning the certification and the internation allocations statement was known to any incident adequated to 37 CFR* 1.56(c) more than three months prior to the filing of the information disclosures statement was known to any incident designated to 37 CFR* 1.56(c) more than three months prior to the filing of the information disclosures.

See attached certification statement.

Fee set forth in 37 CFR 1.17 (p) has been submitted herewith.

None

SIGNATURE

A signature of the applicant or representative is required in accordance with CFR 1.33, 10.18. Please see CFR 1.4(d) for the form of the signature

	VI- 00	()		
Signature	Down	rude	Date (YYYY-MM-DD)	2006-03-27
Name/Print	Gregory L. Gradiey	-0	Registration Number	34,299

This collection of Information is required by 37 CFR, 157 and 1.98. The Information is required to obtain or retain a benefit by the public which is to like (end by the ISPOT to process) an application. Confidentially is governed by 38 US. C 122 and 37 CFR, 1.44. This collection is estimated to take in hour to complete, including agathering, preparing and submitting the completed application from the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Petern and Tradentick (Cflec, U.S. Department of Commency —D. Cles 1450, Alexandria, W. 2231-450, D. ON TS END FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, W. 2231-1460.

Privacy Act Statement

The Privacy Act of 1974 (P.L. 93-579) requires that you be given certain information in connection with your submission of the attached form related to a patient application or patient. Accordingly, pursuant on the requirements of the Act, piesse be expected that: (1) the general authority for the collection of this information is 36 U.S.C. 2(b)(2); (2) furnishing of the information solicated in a violating's and (b) for principal purpose of which the territoriation is used by the U.S. Patient and To-demark Office is to process and for examine your submissions without a patient solicated and the country of the principal purpose of which the territoriation is used by the U.S. Patient and To-demark Office is to process and/or examine your submissions, which may require in termination of proceedings or abandorment of the patient in certain from office processing or abandorment of the application or expendition of the patient.

The information provided by you in this form will be subject to the following routine uses:

- The information on this form will be treated confidentially to the extent allowed under the Freedom of Information Act (5 U.S.C. 552) and the Privacy Act (5 U.S.C. 552a). Records from this system of records may be disclosed to the Department of Justice to determine wherer the Freedom of Information Act requires disclosure of these record s.
- A record from this system of records may be disclosed, as a routine use, in the course of presenting evidence to a
 court, magistrate, or administrative tribunal, including disclosures to opposing counsel in the course of settlement
 necotiations.
- A record in this system of records may be disclosed, as a routine use, to a Member of Congress submitting a request involving an individual, to whom the record pertains, when the individual has requested assistance from the Member with respect to the subject matter of the record.
- A record in this system of records may be disclosed, as a routine use, to a contractor of the Agency having need for the information in order to perform a contract. Recipients of information shall be required to comply with the requirements of the Privacy Act of 1974. as amended, unusuant to 5 U.S.C. 552a/m).
- A record related to an International Application filed under the Patent Cooperation Treaty in this system of records
 may be disclosed, as a routine use, to the International Bureau of the World Intellectual Property Organization, pursuant
 to the Patent Cooperation Treaty.
- A racord in this system of records may be disclosed, as a routine use, to another federal agency for purposes of National Security review (35 U.S.C. 181) and for review pursuant to the Atomic Energy Act (42 U.S.C. 218(c)).
- 7. A record from this system of records may be disclosed, as a routine use, to the Administrator, General Services, or hisher designers, cuting an inspection of records conducted by SSAs a part of that agency's reprostibility to recommend improvements in records management practices and programs, under authority of 44 U.S.C. 2904 and 2506. Such disclosure shall be made in accordance with the GSA regulations powering imprection of records for this purposa, and any other relevant (i.e., GSA or Commerce) directive. Such disclosure shall not be used to make retorminations about Individuals.
- A record from this system of records may be disclosed, as a routine use, to the public after either publication of the application prarent to SS U.S. C. 152 (125) or instance of a patter pursuant to SS U.S. C. 153 (174ther, a record may be disclosed, subject to the imitations of 37 CPR 1.14, as a routine use, to the public if the record was fixed in an application with the record was fixed in an application of the record was fixed in the record was fixed in an application and application on an application one to boddle impressions or an instead patient, which is desirable and application one to boddle impressions or an instead patient,
 - A record from this system of records may be disclosed, as a routine use, to a Federal, State, or local law enforcement agency, if the USPTO becomes aware of a violation or potential violation of law or regulation.